In the Caco-2 CAM model, 5/8 (62%) of tumours in the combination treatment group were negative for cytokeratin and had Ki67 staining less than 50%, similar to the Ribociclib group (62%) and the Alpelisib group (60%). Here, MKI67 is linked to neoplasm.